sglt2 inhibitors and glp-1 receptor agonists inhibitors: a couple at last? Cardiovascular benefits of SGLT2 inhibitors
Description
LIRA did not significantly alter soluble guanylyl cyclase or endothelial nitric oxide synthase (eNOS) mRNA levels, nor total myocardial eNOS protein expression
One reason these drugs are so effective in treating obesity could be that they address the underlying addiction
Eur J Endocrinol
This review aims to discuss the mechanisms, pleiotropic effects, and therapeutic potential of GLP-1, DPP-4, and SGLT2, with a particular focus on their cardiorenal benefits beyond glycemic control
Its main functions are stimulation of insulin secretion in a glucose dependent manner and contribution to fat metabolism in adipocytes
R.AngellottiE.MauroC.et al (2017)
